SCHEMBL4068632

SCHEMBL4068632

CCON=C(c1ccc(CN2CCC3(CC2)OCC2=C3CC(=O)N(C)C2)nc1)c1ccc(F)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 12/20 0.54
KCNH2 Q12809 11/20 0.54
SSTR5 P35346 6/20 0.31
PRCP P42785 1/20 0.31
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073921 0.96 MCHR1 (0.54) MCHR1KCNH2SSTR5PRCPDRD2
SCHEMBL4066968 0.87 KCNH2 (0.69) MCHR1KCNH2SSTR5
SCHEMBL4068573 0.83 MCHR1 (0.50) MCHR1KCNH2SSTR5
SCHEMBL4067112 0.81 MCHR1 (0.61) MCHR1KCNH2SSTR5
SCHEMBL4068629 0.81 MCHR1 (0.77) MCHR1KCNH2
SCHEMBL4073917 0.81 MCHR1 (0.77) MCHR1KCNH2
SCHEMBL4073925 0.81 MCHR1 (0.77) MCHR1KCNH2
SCHEMBL4068633 0.81 MCHR1 (0.77) MCHR1KCNH2
SCHEMBL4068698 0.80 MCHR1 (0.59) MCHR1KCNH2SSTR5
SCHEMBL4075292 0.80 MCHR1 (0.59) MCHR1KCNH2SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US claimed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP claimed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247560-A1 Diaryl ketimine derivative NR0B2, NR2C2, NR3C2 MCHR1 730/4885KCNH2 296/4885SSTR5 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.